Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

Nilesh Kumar

Partner at Novo Ventures

Nilesh joined Novo Ventures (U.S.) Inc. in Boston in 2015. Prior to joining Novo, Nilesh was Senior Director at MS Ventures where he invested in early stage life science companies. Nilesh led the initial investments and served on the Boards of Auxogyn, Canbex, f-Star, Raze Therapeutics, RaNA Therapeutics, Padlock Therapeutics and TocopheRx. In addition to his venture investment role, Nilesh has successfully led several strategic licensing transactions at Merck Serono in oncology and autoimmune therapeutic areas.  Nilesh received his Ph.D. from the Department of Chemistry and Chemical Biology at Harvard University. He holds an M.B.A. from Harvard University, and did his undergraduate degree in Natural Sciences from the University of Cambridge, U.K.